What Do Patients Experience Between Visits, and Why Does It Matter?

Many therapies are approved on surrogate endpoints that often say little about which therapy is best for a patient's needs. In nephrology, IgAN went from zero to six approved therapies in the last 5 years, each first reaching market on a proteinuria endpoint. But does this measure what actually matters to the people living with the disease?

In this webinar, Folia researchers alongside clinician and industry partners will explore a field that has launched several therapies since 2021, what patient's between-visit, home-reported outcomes added to research, and why teams working in any condition should start collecting them.

You'll learn:

1. How structured patient evidence turns anecdotal observations into usable data.
2. How patient insights can reveal treatment impacts never captured as trial endpoints.
3. Why this matters more, not less, once treatments are clinically effective and differentiation shifts to quality of life.
4. How this evidence supports clinicians, clinical development, HEOR, and commercial teams.